News - Medical and health professional investment - VC and PE investment business - Shenzhen Efung Investment Management Co. Ltd.

发布时间: 2025 - 09 - 30

Genuine Biotech's GEN-725 + Doxitinib Mesylate Approved for Clinical Trial

On September 29, 2025, Henan Genuine Biotech Co., Ltd. announced that its self-developed anti-tumor drug GEN-725 in combination with doxitinib mesylate has received approval from the National Medical Products Administration (NMPA) to conduct clinical trials in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring EGFR mutations.GEN-725 is an anti-tumor drug developed by Henan Genuine Biotech Co., Ltd. with independent intellectual property rights. Systematic studies have revealed that GEN-725 exerts its anti-tumor effects through a dual mechanism: (1) as a n...

浏览次数：1

查看详情>>

发布时间: 2025 - 09 - 30

Monthly Health Read | September 2025

n the first half of 2025, the National Medical Products Administration (NMPA) approved 53 new chemical drugs, representing a 43% increase compared to the same period in 2024. Among them, 27 were innovative chemical drugs.This impressive achievement not only reflects the strength of China's pharmaceutical innovation but also serves as the best validation for forward-looking investors. Amid this surging wave of innovation, Efung Capital and its partner pharmaceutical companies have added a brilliant chapter to this remarkable scorecard with their outstanding performance.01 Portfolio Company ...

浏览次数：1

查看详情>>

发布时间: 2025 - 09 - 26

The successful submission of the first share of the new crown oral drug is welcomed by The Hong Kong

Just recently, the Hong Kong Stock Exchange welcomed the successful submission of the first share of the new crown oral drug. On August 4, the Hong Kong Stock Exchange disclosed that Henan Zhenzhen Biotechnology Co., Ltd. (hereinafter referred to as 'Genuine Biotech') submitted a listing application to the Hong Kong Stock Exchange. Efung Capital is the only investment institution to accompany the growth of Genuine Biotech, and it has led two consecutive rounds of investment for the company. The first was in November 2020, when it exclusively led the series A financing of Genu...

浏览次数：5692

查看详情>>

发布时间: 2025 - 09 - 26

Huahaizhongtian's Utidelone Receives Another FDA Orphan Drug Designation | Feng Investment News

On September 25, Beijing Huahaizhongtian Biopharmaceutical Co., Ltd. (hereinafter referred to as "Huahaizhongtian," stock code: 2563.HK) announced that its core product, Utidelone, has been granted another Orphan Drug Designation by the U.S. Food and Drug Administration (FDA), this time for the treatment of pancreatic cancer. This marks the third Orphan Drug Designation granted to Utidelone by the FDA, following those for breast cancer brain metastases and gastric cancer.Pancreatic cancer is a highly malignant tumor, often referred to as the "king of cancers" due ...

浏览次数：1

查看详情>>